KMR-206

• Description:

  KMR-206 is a potent selective PARP7 inhibitor, with an IC50 of 13.7 nM. KMR-206 increases STAT1 and phospho-Tyr701-STAT1 (pSTAT1) . KMR-206 induces STING degradation, increases type I IFN reporter. KMR-206 exhibits anticancer activity against lung adenocarcinoma. KMR-206 can be used in the research of colon cancer[1].

• Target:

  IFNAR; PARP; STAT; STING

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

• Field of Research:

  Cancer

• Smiles:

  N#CC1=CC=C(N2CCN(C(C3=CC(CC4=NNC(C5=C4C=C(C#CC)C=C5)=O)=CC=C3F)=O)CC2)N=C1

• Molecular Formula:

  C29H23FN6O2

• Molecular Weight:

  506.53

• References & Citations:

  [1]Sanderson DJ, et al. Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling. Cell Chem Biol. 2023 Jan 19;30 (1) :43-54.e8.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  IFNAR1; PARP7; STAT1

• CAS Number:

  2992741-10-1